Wechselwirkungen · Hycamtin
HYCAMTIN 0.25 mg hard capsules HYCAMTIN 1 mg hard capsules · Abschnitt 4.5 · PDF-Seite 19
HOS-086087 · Präparat HOS-083256
When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal product may be required to improve tolerability. However, when combining with platinum agents, there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on day 1 or 5 of the topotecan dosing. If either cisplatin or carboplatin is given on day 1 of the topotecan dosing, a lower dose of each agent must be given to improve tolerability compared to the dose of each agent which can be given if the platinum agent is given on day 5 of the topotecan dosing. Currently there is only limited experience in combining oral topotecan with other chemotherapy agents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): platinum (HOS-086055) cisplatin (HOS-086022) carboplatin (HOS-084540)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-20T15:26:00Z · SHA-256 b5faba0cb8dc430e883615daec0cf15a62742b0008cf3a57c33ebf39c2a0a4b9 · Passage acecbcf343a0af793a6a38860e6ab831238ddd2a1ff6f9eaa67ceae1f5f6d34f · Zeichen 902–1598 im Abschnitt